Introduction
============

Hepatocellular carcinoma (HCC) was the third leading cause of cancer mortality worldwide, responsible for more than half a million deaths each year [@B1]. The incidence and mortality in China were about 3 55,595 and 322,417 cases in 2011[@B2]. HCC had strong association with chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) infections, and additionally alcohol abuse [@B3]. Currently, HBV carriers and chronic B hepatitis patients were estimated around 93 million and 30 million in China [@B4].

Mitochondrion (MT) was an extremely important cellular organelle. It was best known for adenosine triphosphate (ATP) production, synthesizing \~95% of energy required for metabolism. MT genome encoded 13 polypeptides of the respiratory chain complexes, as well as 22 transfer RNAs and two ribosomal RNAs participating in mitochondrial protein synthesis [@B5]. Mitochondria also played a key role in the regulation of cellular function and cell apotosis [@B6]-[@B8]. Previous study found that mitochondria had the correlation with tumorigenesis by increasing production of reactive oxygen species (ROS), decreasing oxidative phosphorylation and increasing in glycolysis [@B9]-[@B11].

Oxidative stress was increased in individuals infected with HBV [@B12], [@B13], and the accompanied reactive oxygen was an important inducer of DNA mutations [@B14]. Because of lacking histones and DNA repair system, mutations of MT genome could accumulate to a greater extent [@B15], [@B16]. In the past few years, mutations of MT genome had been widely detected in several types of cancer [@B17]-[@B20]. For instance, mutations of *DLOOP* region had been linked to less differentiated hepatocellular carcinomas (HCC) and with stage progression and prognosis in non-small cell lung cancers [@B21], [@B22]. Many types of human malignancy, including colorectal cancer, liver cancer, breast cancer, lung cancer, prostate cancer, skin cancer and bladder cancer, were related to tumor-specific mutations of MT genome [@B10], [@B23].

Traditionally, the copy number and mutations of MT genome were detected by PCR-based methods. Significant bias could be caused by primer designing and the PCR process. With the rapid development of massively parallel sequencing (MPS) technology, whole genome sequencing (WGS) will bring new insight to the detection of copy number variations and mutations of MT genome.

In this study, published WGS data were used to investigate the heteroplasmic mutations and copy number variations of the mitochondrial genome in 88 pairs of tumor and matched normal samples [@B24]. The result indicated that there was lower copy number of mitochondrial DNA in tumor samples. Heteroplasmic mutations were detected by Mito-seek [@B25], and 241 and 173 heteroplasmic mutations were found in 88 pairs of tumor and matched normal samples. Interestingly, we found that *ND1* gene harbored higher mutation frequency, and nonsynonymous mutations were more frequently detected in tumor samples. In particular 202 mutations were detected only in tumor samples. The data of copy number variations and heteroplasmic mutations could provide the basis for further understanding mechanism of tumorigenesis.

Materials and Methods
=====================

Samples and data preparation
----------------------------

We studied 88 Chinese individuals who were diagnosed with HCC at Queen Mary Hospital. Sample collection and whole genome sequencing had been described in the previous publication [@B24]. Written informed consents were obtained from each patient. The study protocol was approved by the Institutional Review Board of Queen Mary Hospital [@B26]. The data was anonymized before the whole genome sequence data was accessed. Sequence data had been deposited in the European Nucleotide Archive (ENA, <http://www.ebi.ac.uk/ena/>) under accession number ERP001196 and in GigaDB (<http://dx.doi.org/10.5524/100034>).

Heteroplasmic Mutations Calling and Copy number Calculation
-----------------------------------------------------------

Low-quality and adaptor-contamination reads were removed to obtain clean reads for subsequent analysis; meanwhile, MT genome (NC_012920) was used as reference. Then clean reads were aligned to this reference genome by using the BWA software [@B27]. A mapping quality score was assigned to each alignment by BWA. After removing the PCR duplicates and low mapping quality (Q\<10) reads, we used the Mito-seek software to call heteroplasmic mutations [@B25]. In each sample, we calculated the copy number of MT genome according to the ratio of the average depth of MT genome vs whole human genome. The equation we used to calculate the copy number of MT genome was as followed:

Results
=======

Copy number variations and heteroplasmic mutations between tumor and normal samples
-----------------------------------------------------------------------------------

To evaluate whether or not any changes of MT genome within the HCC patients, we compared the copy number of MT genome between the tumor samples and their matched normal samples in the 88 HCC patients. The average copy number of MT genome in the normal samples was significantly higher than that in tumor samples (FIG.[1](#F1){ref-type="fig"}a, p-value\<0.01, T-test). The average copy number of MT genome was 453 and 532 in the tumor samples and their adjacent normal samples, respectively (Table [S1](#SM0){ref-type="supplementary-material"}).

There were 241 and 173 heteroplasmic mutations in tumor and normal samples, respectively (Table [S1](#SM0){ref-type="supplementary-material"}, Table [S2](#SM0){ref-type="supplementary-material"}). We found higher positive ratio of heteroplasmic mutation in tumor samples 86% (76/88) than that in normal samples 73%(65/88) (FIG.[1](#F1){ref-type="fig"}b, p-value\<0.01,Chi-Squared test). Next, we surveyed the heteroplasmic ratio of heteroplasmic mutations. There was significant higher heteroplasmic ratio in tumor samples than that in normal samples. Next we divided these heteroplasmic mutations of tumor and normal samples into synonymous and nonsynonymous mutations and surveyed the difference of heteroplasmic ratio. The results revealed that there was higher heteroplasmic ratio of nonsynonymous mutations in tumor samples (FIG.[1](#F1){ref-type="fig"}c, p\<0.05, T-test).

The Inclination of Heteroplasmic Mutations
------------------------------------------

We first surveyed the frequency of heteroplasmic mutations in these 88 individuals. It revealed that heteroplasmic mutation was prone to occur in the region of *DLOOP* (FIG.[2](#F2){ref-type="fig"}). The highest frequency of heteroplasmic mutation was C312A of mitochondrial genome in the tumor and normal samples.

We also calculated the mutation frequency of genes and found the top 6 genes of tumor samples were *DLOOP(41), RNR2(17), ND5(13), ND1(13), CYTB(12), ND2(10)* and the normal samples were *DLOOP(50), ND4(11), RNR2(8), ND5(7), CYTB(7), ND1(4)* (FIG.[3](#F3){ref-type="fig"}). The results of comparing mutation frequency of genes between tumor and normal samples showed that *ND1* and *ND2* have higher mutation frequency in tumor samples (Table [S3](#SM0){ref-type="supplementary-material"}). Meanwhile, the ratio of nonsynonymous versus synonymous heteroplasmic mutations in *ND1* genes was greater in tumor samples (p\<0.01, Chi-squared test) (Table [1](#T1){ref-type="table"}).

The specific heteroplasmic mutations of tumor
---------------------------------------------

In order to analyse the characteristics of tumor-specific heteroplasmic mutations in 88 HCC patients, heteroplasmic mutations shared by tumor and normal samples were filtered out, and consequently obtained 202 tumor-specific mutations in 68 tumor samples (Table [S4](#SM0){ref-type="supplementary-material"}). Overall, 32 synonymous and 67 nonsynonymous mutations were found in 68 samples (Table [S5](#SM0){ref-type="supplementary-material"}). Moreover, *ND1, ND3, ND4, ND5* and *ND6* genes had higher ratio of nonsynonymous versus synonymous mutations in tumor-specific heteroplasmic mutations. Among those 202 tumor-specific mutations, it is noted that six genes (*DLOOP(28), RNR2(15), ND1(13), CYTB(11), ND5(11)* and *ND2(10)*) were more frequently mutated (≥10 samples) than others (Table [S6](#SM0){ref-type="supplementary-material"}).

Discussion
==========

In this study, we had studied the copy number of MT genome in 88 pairs of HCC tumor and matched normal samples, revealing the tumor samples possessed significantly lower copy number than the matched normal samples. This is consistent with previous studies in HCC [@B28]. The reduced copy number in tumor samples had high possibility to be link to the functional defects of mitochondria [@B29], [@B30].

Tumor samples not only had more heteroplasmic mutations, but also contained higher heteroplasmic ratio of heteroplasmic mutations than those normal samples. The phenomenon might indicate that there is higher cumulative mutation frequency in tumor samples. Accompany with the development of tumorigenesis, these heteroplasmic mutations of tumor samples might be accumulated effectively. Interestingly, there was also higher heteroplasmic ratio among these nonsynonymous mutations in tumor samples than in normal samples (p\<0.05, T-Test), however no significant difference among these synonymous mutations. It might suggest that these nonsynonymous mutations might have a certain role in promoting tumorigenesis.

Furthermore, comparing the mutation frequency between tumor and normal samples, *ND1* and*ND2* had been found to have higher mutation frequency in tumor than normal samples. Additionally, *ND1* gene included more nonsynonymous sties than synonymous mutations in tumor samples. Therefore, suggesting heteroplasmic mutations in *ND1* might have an important contribution to tumorigenesis. In addition, it was observed that *ND1, ND3, ND4, ND5, ND6* genes harbored more nonsynonymous than synonymous mutations in tumor-specific mutations. Bear in mind, these genes had been known to be part of complex I. Therefore, it suggested that nonsynonymous mutations of Complex I might be closely related to tumorigenesis. Moreover, nonsynonymous mutations could result in amino acid substitutions and disrupt the function of mitochondrial genes. The accumulation of certain mutations in the mitochondrial genome had been found to lead to deficiency in mitochondrial respiration and ATP generation [@B19], [@B28], [@B31]. For instance, mutations and dysfunction of *ND5* are linked to promote the tumorigenesis through ROS alteration and AKT activation. Cell line carrying the heteroplasmic mutation in complex I manifested tumor growth enhancement, because dysfunctional Complex I could alter redox ratio (NADH/NAD) and activation of AKT pathway [@B32], [@B33]. Hereby, this study supplied evidence further suggesting nonsynonymous mutations of Complex I might have close relationship with tumorigenesis. Moreover, the copy number variation and heteroplasmic mutations in HCC samples could provide the basis for further understanding mechanism of tumorigenesis.
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![**The copy number and heteroplasmic mutations of tumor and normal samples** (a) represented that the difference of copy number variation in tumor and normal samples (T-test, p\<0.01). (b) represented the difference of the ratio of samples with heteroplasmic mutations between tumor and normal samples (Chi-squared test, p\<0.01). (c)represented that comparing the heteroplasmic ratio of heteroplasmic mutations in tumor and normal samples (T-test, p\<0.05) and comparing the heteroplasmic ratio of nonsynonymous mutations in tumor and normal samples (T-test, p\<0.05).](jcav08p4011g001){#F1}

![**The distribution of mutation frequency of heteroplasmic sites in tumor and normal samples.** The figure showed the distribution of mutation frequency in tumor and normal samples. The inner circle revealed the distribution of mutation frequency in normal samples and the outer circle revealed the distribution of mutation frequency in tumor samples.](jcav08p4011g002){#F2}

![**Comparison of mutation frequency between tumor and normal samples** The figure showed the difference of mutation frequency in tumor and normal samples. The inner circle revealed the distribution of gene frequency in normal samples and the outer circle revealed the distribution of gene frequency in tumor samples.](jcav08p4011g003){#F3}

###### 

The number of synonymous and nonsynonymous mutations

  Gene   The number of tumor synonymous mutation   The number of tumor nonsynonymous mutation   The number of normal synonymous mutation   The number of normal nonsynonymous mutation
  ------ ----------------------------------------- -------------------------------------------- ------------------------------------------ ---------------------------------------------
  ND4    5                                         6                                            7                                          5
  ND1    3                                         12                                           4                                          1
  ATP8   0                                         2                                            0                                          1
  CYTB   5                                         11                                           2                                          9
  ND5    4                                         12                                           1                                          6
  ND2    7                                         8                                            3                                          2
  ATP6   0                                         3                                            0                                          2
  COX3   2                                         2                                            1                                          4
  ND3    3                                         5                                            4                                          3
  COX1   4                                         3                                            3                                          4
  ND6    1                                         3                                            2                                          1
  COX2   1                                         4                                            1                                          1
  ND4L   0                                         3                                            0                                          3

The table showed that the number of synonymous and nonsynonymous mutations in tumor and normal samples.
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